Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

科研成果: 期刊稿件文章同行评审

136 引用 (Scopus)

指纹

探究 'Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy' 的科研主题。它们共同构成独一无二的指纹。

Medicine and Dentistry

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science